| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
11,270,000 |
| Market
Cap: |
290.99(M) |
| Last
Volume: |
197,427 |
Avg
Vol: |
196,876 |
| 52
Week Range: |
$13.82 - $26.35 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile XOMA is a biotech royalty aggregator. Co. has a portfolio of economic rights to milestone and royalty payments associated with partnered pre-commercial therapeutic candidates. Co.'s portfolio was built through licensing its proprietary products and platforms from its discovery and development business, combined with acquisitions of rights to milestones and royalties.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
14,600 |
117,800 |
| Total Buy Value |
$0 |
$0 |
$268,048 |
$2,088,813 |
| Total People Bought |
0 |
0 |
2 |
3 |
| Total Buy Transactions |
0 |
0 |
13 |
21 |
| Total Shares Sold |
0 |
0 |
0 |
27,000 |
| Total Sell Value |
$0 |
$0 |
$0 |
$809,425 |
| Total People Sold |
0 |
0 |
0 |
2 |
| Total Sell Transactions |
0 |
0 |
0 |
2 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Varian John |
Director |
– • – |
2017-05-16 |
4 |
S |
$6.24 |
$246,919 |
D/D |
(39,540) |
2,344 |
|
- |
|
| Neal James R |
VP Business DevelopmentVP Busi |
• • – |
2017-03-21 |
4 |
S |
$5.40 |
$27,569 |
D/D |
(5,105) |
15,366 |
|
- |
|
| Burns Thomas M. |
VP, Finance & Chief Financial |
• – – |
2017-03-21 |
4 |
S |
$5.40 |
$14,030 |
D/D |
(2,598) |
6,555 |
|
- |
|
| Perry Matthew D |
See Explanation of Responses |
– • – |
2017-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
11,799 |
11,799 |
|
- |
|
| Lampert Mark N |
10% Owner |
– – • |
2017-02-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,270,922 |
|
- |
|
| Neal James R |
VP Business DevelopmentVP Busi |
• – – |
2017-02-01 |
4 |
AS |
$4.50 |
$881 |
D/D |
(195) |
20,471 |
|
- |
|
| Neal James R |
VP Business DevelopmentVP Busi |
• – – |
2017-01-09 |
4 |
AS |
$5.15 |
$644 |
D/D |
(125) |
20,666 |
|
- |
|
| Varian John |
Director |
– • – |
2016-12-21 |
4 |
S |
$5.75 |
$77,907 |
D/D |
(13,549) |
41,884 |
|
- |
|
| Scannon Patrick J Md Phd |
Exec. VP & CSOExec. VP & CSO |
• – – |
2016-12-21 |
4 |
S |
$5.75 |
$18,573 |
D/D |
(3,230) |
8,217 |
|
- |
|
| Neal James R |
VP Business Development |
• – – |
2016-11-01 |
4 |
AS |
$5.25 |
$788 |
D/D |
(150) |
20,541 |
|
- |
|
| Neal James R |
VP Business DevelopmentVP Busi |
• – – |
2016-10-07 |
4 |
AS |
$0.45 |
$1,120 |
D/D |
(2,500) |
413,839 |
|
- |
|
| Walbert Timothy P |
Director |
– • – |
2016-07-21 |
4 |
A |
$0.00 |
$0 |
D/D |
48,246 |
129,314 |
|
- |
|
| Wyszomierski Jack L |
Director |
– • – |
2016-07-21 |
4 |
A |
$0.00 |
$0 |
D/D |
48,246 |
129,314 |
|
- |
|
| Van Ness W Denman |
Director |
– • – |
2016-07-21 |
4 |
A |
$0.00 |
$0 |
D/D |
48,246 |
139,596 |
|
- |
|
| Limber Joseph M |
Director |
– • – |
2016-07-21 |
4 |
A |
$0.00 |
$0 |
D/D |
48,246 |
124,219 |
|
- |
|
| Wyszomierski Jack L |
Director |
– • – |
2016-05-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,800 |
81,068 |
|
- |
|
| Walbert Timothy P |
Director |
– • – |
2016-05-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,800 |
81,068 |
|
- |
|
| Van Ness W Denman |
Director |
– • – |
2016-05-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,150 |
91,350 |
|
- |
|
| Limber Joseph M |
Director |
– • – |
2016-05-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,800 |
75,973 |
|
- |
|
| Burns Thomas M. |
VP, Finance & Chief Financial |
• – – |
2016-03-22 |
4 |
S |
$0.78 |
$15,105 |
D/D |
(19,249) |
183,071 |
|
- |
|
| Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
• – – |
2016-03-22 |
4 |
S |
$0.78 |
$18,985 |
D/D |
(24,194) |
326,601 |
|
- |
|
| Neal James R |
VP Business DevelopmentVP Busi |
• – – |
2016-03-22 |
4 |
S |
$0.78 |
$15,547 |
D/D |
(19,813) |
411,339 |
|
- |
|
| Scannon Patrick J Md Phd |
Exec. VP & CSO |
• • – |
2016-03-22 |
4 |
S |
$0.78 |
$11,602 |
D/D |
(14,785) |
228,942 |
|
- |
|
| Varian John |
CEO |
• • – |
2016-03-22 |
4 |
S |
$0.78 |
$63,578 |
D/D |
(81,022) |
1,108,673 |
|
- |
|
| Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
• – – |
2016-03-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,141 |
350,795 |
|
- |
|
594 Records found
|
|
Page 7 of 24 |
|
|
0.48 (1.89%) 
